Statins have been widely used for the treatment of a variety of medical conditions including psychoneurological disorders beyond their original use in lowering cholesterol. Histamine receptors play an important role in the regulation of neural activity, however, it is unknown whether statins act on histamine receptors, particularly for their neural regulatory effects. This study examined the effects of simvastatin and 6-hydroxydopamine (6-OHDA) lesions on histamine H1 receptors using [ 3 H] pyrilamine binding autoradiography. Compared to the saline group, simvastatin (1 mg/kg/day) significantly decreased H1 receptor bindings in the primary motor cortex (M1), ventromedial hypothalamic nucleus (VMH), caudate putamen (CPu), accumbens core (AcbC) and prefrontal cortex (PfC) (all p b 0.05); however 10 mg/kg/day simvastatin increased H1 receptor density only in the medial amygdaloid nucleus (Mep) (p b 0.05), but had no significant effect in other regions examined. The 6-OHDA lesion did not alter H1 receptor binding density in most brain areas, except a trend decrease in the hippocampus (p = 0.07) and a trend increase in the cingulate cortex (p = 0.06). These results suggested that simvastatin has different effects on the H1 receptors in different rat brain regions depending on the doses. Therefore, simvastatin can modulate histaminergic neurotransmission in the brain, and support the role of H1 receptors in psychoneurological disorders.
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Introduction
Belonging to the family of G protein coupled receptors (GPCR), histamine H1, 2 and 3 receptors are abundantly distributed in the brain while H4 receptors are mainly expressed in the peripheral tissues (De Esch et al., 2005) . As one of the main histamine receptors, H1 receptors are found in the thalamus, hypothalamus, brainstem nuclei, amygdala, hippocampus, and prefrontal cortex (Martinez-Mir et al., 1990) . H1 receptors are associated with an intracellular G protein (G q ) that activates the phospholipase C, and diacylglycerol (DAG)-sensitive activation of protein kinase C (PKC), phosphatidylinositol (PIP2) signaling pathways. It has been shown that H1 receptors are involved in many important brain functions, including working memory, feeding rhythms, energy metabolism, sleeping, mood, pain and inflammation (Haas et al., 2008) . Various neuropsychological disorders may lead to changes in central H1 receptors in different brain regions. The higher expression of H1 receptor binding in anorexia nervosa (AN) patients was observed in the limbic system including the amygdala, hippocampus, medial prefrontal cortex, orbitofrontal cortex and temporal cortex (Yoshizawa et al., 2009) . Iwabuchi et al. (2005) found that the binding densities of H1 receptors in the frontal, prefrontal and the cingulate cortices were significantly decreased in schizophrenic patients compared to the control subjects. On the contrary, an elevation of H1 receptor binding was detected in the foci of epileptic patients with complex partial seizures (Iinuma et al., 1993) . Taken together, these findings strongly suggest that H1 receptors play important roles in some neurological dysfunctions.
Statins, the inhibitor of rate-limiting enzyme-hydroxymethylglutaryl-coenzyme reductase, have been widely used for lowering cholesterol. In addition, increasing evidence showed that statins have potential medical applications in various diseases such as peripheral arterial disease, stroke, traumatic brain injury, and the end-stage of renal disease, diabetes mellitus, multiple sclerosis, and Alzheimer's disease. Recent studies showed that statins exhibited profoundly neuroprotective effects on dopaminergic neurodegeneration (Ghosh 
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